ARTICLE | Company News
Palmetto to cover Genomic Health's prostate cancer test
August 18, 2015 1:01 AM UTC
Genomic Health Inc. (NASDAQ:GHDX) rose $1.94 to $26.79 after it said Medicare administrative contractor Palmetto GBA LLC issued a local coverage determination (LCD) that covers the company's Oncotype Dx prostate cancer assay for qualified patients. The LCD takes effect on Oct. 1.
Palmetto will cover the test for prostate cancer patients who are defined as low or very low-risk by National Comprehensive Cancer Network (NCCN) guidelines and who meet additional criteria in order to help identify patients who can be "conservatively managed" rather than treated with surgery or radiation therapy. ...